AbCellera Biologics Eyes Integrated Biotech Shift; ABCL635 Phase II Data Due in Q3 at Forum [Yahoo! Finance]
AbCellera Biologics Inc. - Common Shares (ABCL)
Company Research
Source: Yahoo! Finance
AbCellera Biologics (NASDAQ:ABCL) is working to evolve from a technology-enabled drug discovery partner into what the company described as an integrated biotech with internal programs advancing through mid- to late-stage development, according to comments from Senior Director of Strategic Finance and Investor Relations Martin Hogan during a KeyBanc Virtual Healthcare Forum fireside chat. Building an integrated antibody discovery and development platform Hogan said AbCellera's journey spans roughly 13 years, with significant technology investment during its first decade to build capabilities ranging from target nomination through manufacturing drug product for antibody-based therapeutics. He said experience across more than 100 drug discovery programs has helped AbCellera assemble an integrated capability intended to pursue difficult antibody targets. That platform, he said, has supported partner programs that can generate downstream stakes, while also enabling a growing pipeline
Show less
Read more
Impact Snapshot
Event Time:
ABCL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABCL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABCL alerts
High impacting AbCellera Biologics Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
ABCL
News
- AbCellera Biologics Pivots to Pipeline as ABCL635 Phase II Hot Flash Data Nears, Exec Says [Yahoo! Finance]Yahoo! Finance
- AbCellera Biologics (ABCL) Pivots to Clinical Stage as 2025 Revenue Hits $75M [Yahoo! Finance]Yahoo! Finance
- AbCellera Biologics Inc (ABCL) Q4 2025 Earnings Call Highlights: Navigating Growth Amidst Challenges [Yahoo! Finance]Yahoo! Finance
- AbCellera Biologics Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- AbCellera Reports Full Year 2025 Business ResultsBusiness Wire
ABCL
Earnings
- 2/24/26 - Beat
ABCL
Sec Filings
- 3/2/26 - Form 4
- 2/27/26 - Form 4
- 2/27/26 - Form 4
- ABCL's page on the SEC website